Literature DB >> 7036425

Chloroquine sensitivity of Plasmodium falciparum in Ibadan, Nigeria: II. Correlation of in vitro with in vivo sensitivity.

A F Aderounmu, L A Salako, O Walker.   

Abstract

Plasmodium falciparum malaria was treated in 82 children with 25 mg/kg chloroquine orally over three days. They were observed for 28 days during which blood films were examined periodically for malaria parasites. Asexual forms of P. falciparum, present in the blood films of all the patients before commencing treatment, disappeared rapidly and by the third day no parasites were seen in blood films from any of them. Among the patients observed for more than three days, blood films remained negative throughout the observation period. In vitro tests of sensitivity of blood samples from 10 patients showed chloroquine concentrations of 0.5 to 0.8 nmol/ml to inhibit completely maturation from ring forms to schizonts. This suggests that P. falciparum in the Ibadan area is probably still fully sensitive to chloroquine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7036425     DOI: 10.1016/0035-9203(81)90138-3

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  3 in total

Review 1.  Chemoprophylaxis of malaria in Africa: the spent "magic bullet".

Authors:  L J Bruce-Chwatt
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11

2.  Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria.

Authors:  O Walker; A H Dawodu; A A Adeyokunnu; L A Salako; G Alvan
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

3.  Potential contribution of prescription practices to the emergence and spread of chloroquine resistance in south-west Nigeria: caution in the use of artemisinin combination therapy.

Authors:  Grace O Gbotosho; Christian T Happi; Abideen Ganiyu; Olumide A Ogundahunsi; Akin Sowunmi; Ayoade M Oduola
Journal:  Malar J       Date:  2009-12-30       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.